Tag: 5356

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy^® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity.

Novo Nordisk’s sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six...

Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTags5356

NYSE Content Update: Intercontinental Exchange Joins Anthropic’s Project Glasswing

Mercedes-Benz of Westwood Celebrates Grand Opening of Newly Renovated Luxury Dealership

Star Living Introduces Integrated ‘One-Stop Home & Living’ Concept to Simplify Renovation and Furnishing for Singapore Homeowners

Tag: 5356

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

Novo Nordisk’s sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six...

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us